CTLA4 and hepatocellular carcinoma: In a phase II trial evaluating the effect of tremelimumab (CTLA-4 antibody) in HCV-related HCC patients, the antitumor effect was remarkable, with a partial response (PR) rate of 17.6% and TTP of 6.5 months [152].